Lancaster Laboratories appoints biologics expert

Jeri Ann Boose joins the company

Biologics expert Jeri Ann Boose has joined Lancaster Laboratories, part of Thermo Fisher Scientific, as director of biopharmaceutical services.

Boose will provide strategic, scientific and regulatory direction for the company’s rapidly expanding biopharmaceutical testing business, which includes biochemistry, cell and molecular biology and virology capabilities. She has expertise in the formulation of global regulatory product testing strategies and in the preparation of global regulatory filings, as well as commercialisation of new products for biopharmaceutical customers.

‘The combination of Dr Boose’s renowned expertise in biologics, coupled with our comprehensive biopharmaceutical capabilities, clearly positions Lancaster Laboratories as a leading provider of services to support the development and commercialisation of biologics products,’ said Timothy Oostdyk, executive vice president and chief operating officer of Lancaster Laboratories.

You may also like

Hi Tech Manufacturing

Thermo Fisher scientific launches iCAP MX series ICP-MS for trace elemental analysis

New platform simplifies analysis while enhancing productivity and accuracy
Regulatory

Quality harmonisation: how CDMOs ensure a consistent, reliable and resilient supply chain

From innovative oral solid dose formulations to steriles and biologics, access to cutting-edge technology enables pharmaceutical manufacturing teams to meet the needs of nuanced drug development processes
Manufacturing

Thermo Fisher achieves ISO certification

Accreditation certificate number 6559.01 was granted by the American Association for Laboratory Accreditation (A2LA)
Analysis

Moving forward with N-nitrosamine analysis

The June 2018 discovery of N-nitrosodimethylamine (NDMA) in the active pharmaceutical ingredient (API) of valsartan led to unprecedented activity by health authorities and the pharmaceutical industry to understand the root causes and mitigate the presence of these potentially carcinogenic impurities in pharmaceutical products<sup>1,2</sup>
Manufacturing

Thermo Fisher launches next-gen mass spectrometry solutions at summit

The new systems and software tools support scientists working across a wide range of applications, from proteomics studies and biotherapeutics to food testing and clinical applications
Manufacturing

Thermo Fisher launches first cleanroom-compatible CO2 incubator for cell culture

Thermo Fisher has designed the cell growth incubator with in-chamber HEPA filtration, on-demand 180°C sterilisation and an optional 100% pure copper interior chamber
Finance

Thermo Fisher to put more than $600m into bioprocessing globally

These investments are expected to more than double the company's current manufacturing capacity across 11 manufacturing sites in the Americas, Europe and Asia
Subscribe now